Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Moderna

Bird flu vaccines in development

As part of the Biden admin's pandemic preparedness strategy, Moderna will develop an mRNA vaccine for H5N1

Salon

Moderna Dives 11% After RSV Vaccine Proves Less Effective Than Pfizer, GSK Shots

Moderna stock tumbled Wednesday after the company said its newly approved RSV vaccine was only about 50% effective after 18 months.

Investors Business Daily

Is Moderna Stock Outperforming the S&P 500?

Moderna recently outperformed the S&P 500, and Wall Street analysts are moderately optimistic about the stock’s prospects.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Results are looking promising for a combined COVID and flu vaccine. Here’s how it could benefit public health

Earlier this week, Moderna announced positive results for its phase 3 clinical trial of a combined vaccine against COVID and influenza.

The Conversation

2-in-1 shot for flu and COVID shows promise in advanced trial

The pharmaceutical company Moderna announced promising results from the ongoing trial of its new vaccine, mRNA-1083.

LiveScience

Moderna combi flu and Covid jab gives better protection, study finds

Clinical trials show two-in-one jab may bring about higher immune responses than separate inoculations

The Guardian - UK

Combined Covid and flu vaccine could be approved for use on NHS by next year

New vaccine could cut need for separate Covid and flu jabs

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

Moderna Says Combination Flu And Covid Vaccine Beat Out Rivals From Sanofi, GSK

Moderna said Monday its Covid/flu vaccine topped rivals from GSK and Sanofi, and its own Spikevax shot. But Moderna stock fell.

Investors Business Daily

FDA advisers urge targeting JN.1 strain in recipe for fall's COVID vaccines

Government advisers say it’s time to update the recipe for the COVID-19 vaccines Americans will receive in the fall

The Independent UK

‘Extremely impressive’: melanoma jab trial results excite doctors

Vaccine approach will help improve survival rates for ‘the next decades and more’, says Cancer Research UK’s chief clinician

The Guardian - UK

Bird flu vaccines face a problem: eggs

Fertilized hen eggs are still the main ingredient in making vaccines that may protect us against H5N1

Salon

Scientists are testing mRNA vaccines to protect cows and people against bird flu

The bird flu outbreak in U.S. dairy cows is prompting development of new, next-generation mRNA vaccines — akin to the shots deployed during the COVID-19 pandemic

The Independent UK

Moderna Wins FDA Approval For Second-Ever Product; Why Its RSV Vaccine Could Dominate Pfizer, GSK

The FDA approved Moderna's RSV vaccine, allowing the biotech to launch its second-ever product. But Moderna stock retreated.

Investors Business Daily

Is This Biotech Stock's OpenAI Partnership a Game-Changer?

With AI making waves in biotech, could this biotech’s OpenAI partnership be the catalyst for new highs?

Barchart

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

The U.S. Is Close To Bankrolling Moderna's Bird Flu Vaccine As Third Dairy Worker Tests Positive

Moderna stock seesawed Thursday after confirming the U.S. government is nearing a deal to fund its pandemic bird flu vaccine.

Investors Business Daily

Option Trade On Volatile Moderna Stock Could Return 28% By Mid-July

This iron condor trade on Moderna stock has the potential to return 28% if the stock price stays between 118.90 and 181.10.

Axios

Novavax strikes $1.2 billion deal with Sanofi in major turnaround

It's a major turnaround for a drug company that warned last year about its ability to stay in business.

Investors Business Daily

Moderna Tumbles After The FDA Throws A Curveball On Its Second Product

Moderna stock toppled Friday after the FDA delayed an approval decision on its RSV vaccine until the end of the month.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Moderna Breaks Out For The First Time In A Year After Covid Shot Wallops Sales Views

Moderna stock broke out for the first time in a year Thursday after beating first-quarter expectations as its second potential approval looms.

AAP

Coroner probes vaccine link to young woman's death

A Victorian coroner is investigating whether a woman's death from heart inflammation after receiving her third COVID-19 jab was due to the Moderna vaccine.

The Street

Cathie Wood sells $48 million of cloud tech stock

Her Ark Innovation ETF has slipped 3.4% so far this year.

Investors Business Daily

Dow Jones Climbs As Donald Trump Stock Dives; Cathie Wood Loads Up On This Amid 42% Plunge

The Dow Jones gained on the stock market today. A Donald Trump-linked entity fell while Cathie Wood bought a diving stock.

StockNews.com

Biotech Investors: Should You Buy, Hold, or Sell Moderna (MRNA) and Arrowhead Pharmaceuticals (ARWR)?

Despite facing several challenges, the biotech sector thrives due to growing demand for effective treatments, consistent innovations, and a sustained demand for high-quality drugs and therapies. Let's assess whether one should Buy, Hold, or Sell biotech stocks Moderna (MRNA) and Arrowhead Pharmaceuticals (ARWR). Keep reading.

The Guardian - UK

Covid vaccines cut risk of virus-related heart failure and blood clots, study finds

Researchers say jabs substantially reduce for up to a year the chances of serious cardiovascular complications

Barchart

Stocks Close Mildly Lower on Caution Ahead of Tuesday’s U.S. CPI Report

The S&P 500 Index ($SPX ) (SPY ) on Monday closed down -0.11%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.12%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed -0.37%. Stocks Monday traded mildly lower on a +2.3 bp rise in the 10-year T-note...

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.